25 related articles for article (PubMed ID: 7699050)
1. Susceptibility Test Interpretive Criteria and the Benefit of Diverse Viewpoints.
Humphries R
Clin Infect Dis; 2024 Jun; ():. PubMed ID: 38902918
[No Abstract] [Full Text] [Related]
2. Interpretive criteria and quality control parameters for testing bacterial susceptibility to the fluoroquinolone PD131628.
Barry AL; Fuchs PC; Allen SD; Tenover FC; Jorgensen JH; Reller LB
J Clin Microbiol; 1995 Jan; 33(1):235-8. PubMed ID: 7699050
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility testing and quality control parameters for sarafloxacin (A-56620): a fluoroquinolone used for treatment and control of colibacillosis in poultry. Quality Control Study Group.
Jones RN; Erwin ME
Diagn Microbiol Infect Dis; 1998 Sep; 32(1):55-64. PubMed ID: 9791759
[TBL] [Abstract][Full Text] [Related]
4. Proposed quality control and interpretive criteria for disk diffusion susceptibility testing with enoxacin.
Rudrik JT; Cavalieri SJ; Britt EM
J Clin Microbiol; 1985 Mar; 21(3):332-4. PubMed ID: 3856570
[TBL] [Abstract][Full Text] [Related]
5. Calibration of the disk diffusion test for trovafloxacin susceptibility testing of four anaerobic species.
Kronvall G; Holst E
Clin Microbiol Infect; 2000 Apr; 6(4):195-201. PubMed ID: 11168107
[TBL] [Abstract][Full Text] [Related]
6. Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-microgram) diffusion methods. The Quality Control Study Group.
Jones RN; Kugler KC; Erwin ME; Biedenbach DJ; Beach ML; Pfaller MA
Diagn Microbiol Infect Dis; 1999 Apr; 33(4):247-53. PubMed ID: 10212751
[TBL] [Abstract][Full Text] [Related]
7. Tentative interpretive criteria and quality control parameters for in-vitro susceptibility testing of Neisseria gonorrhoeae to two fluoroquinolones (PD 131628 and grepafloxacin (OPC 17116)).
Sewell DL; Barry AL; Allen SD; Fuchs PC; Murray PR; Tenover FC
J Antimicrob Chemother; 1996 Jan; 37(1):139-43. PubMed ID: 8647755
[TBL] [Abstract][Full Text] [Related]
8. Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin.
Barry AL; Fuchs PC; Citron DM; Allen SD; Wexler HM
J Antimicrob Chemother; 1993 Jun; 31(6):893-900. PubMed ID: 8395494
[TBL] [Abstract][Full Text] [Related]
9. In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents.
Ford AS; Baltch AL; Smith RP; Ritz W
J Antimicrob Chemother; 1993 Apr; 31(4):523-32. PubMed ID: 8390434
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial activity of PD 131628 and proposed disc diffusion susceptibility test criteria.
Fuchs PC; Barry AL; Pfaller MA
J Antimicrob Chemother; 1994 Jun; 33(6):1147-54. PubMed ID: 7928808
[TBL] [Abstract][Full Text] [Related]
11. Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study.
Gavan TL; Jones RN; Barry AL; Fuchs PC; Gerlach EH; Matsen JM; Reller LB; Thornsberry C; Thrupp LD
J Clin Microbiol; 1981 Jul; 14(1):67-72. PubMed ID: 6455443
[TBL] [Abstract][Full Text] [Related]
12. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.
Fuchs PC; Barry AL; Pfaller MA; Allen SD; Gerlach EH
Antimicrob Agents Chemother; 1991 Apr; 35(4):764-6. PubMed ID: 2069384
[TBL] [Abstract][Full Text] [Related]
13. Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin.
Barry AL; Fuchs PC
Eur J Clin Microbiol Infect Dis; 1991 Mar; 10(3):168-71. PubMed ID: 2060518
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
